Neuphoria Therapeutics (NEUP) Research & Development (2023 - 2025)
Neuphoria Therapeutics (NEUP) posted quarterly Research & Development of $697723.0 for Q4 2025, down 59.83% year-over-year from $1.7 million in Q4 2024, and down 81.57% quarter-over-quarter from $3.8 million in Q3 2025.
Neuphoria Therapeutics (NEUP) Research & Development (2023 - 2025) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Research & Development for 3 consecutive years, with $697723.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 59.83% year-over-year to $697723.0; the TTM figure through Dec 2025 stood at $9.9 million (up 24.18% YoY), while the FY2025 annual figure was $9.0 million, down 4.38% from the prior year.
- Research & Development declined to $697723.0 in Q4 2025 per NEUP's latest filing, from $3.8 million in the prior quarter.
- Across five years, Research & Development topped out at $3.8 million in Q3 2025 and bottomed at $697723.0 in Q4 2025.
- Historically, Research & Development has averaged $2.3 million across 3 years, with a median of $2.0 million in 2023.
- On a YoY basis, Research & Development climbed as much as 99.15% in 2025 and fell as far as 59.83% in 2025.
- Neuphoria Therapeutics' Research & Development stood at $2.0 million in 2023, then fell by 14.64% to $1.7 million in 2024, then plunged by 59.83% to $697723.0 in 2025.
- Business Quant data shows NEUP's Research & Development at $697723.0 in Q4 2025, $3.8 million in Q3 2025, and $3.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 697,723.00 |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 2.03 Mn |
| Sep 30, 2023 | 3.09 Mn |